Unlocking Growth in Surgical Robotics: Procept BioRobotics Undervalued

Procept BioRobotics is a surgical robotics company that may be undervalued, despite its growth potential. The company's SPYRAL HTL and SPYRAL RCT trials for the treatment of hypertension have shown positive results, and the FDA has granted Breakthrough Device designation to the SPYRAL HTL trial. Procept's SPYRAL system has the potential to be a game-changer in the treatment of hypertension, and the company's shares may be worth considering for investors looking for a growth story in the surgical robotics space.